Stop Addiction Stigma

Stop Addiction Stigma Training Workshop With Case Vignettes to Decrease Stigmatizing Attitudes Toward People With Substance Abuse Disorders

This clinical trial evaluates the impact of a Stop Addiction Stigma (SAS) training workshop with a short description of the conditions related to addiction (vignettes) on stigmatizing attitudes toward individuals with substance abuse disorders. Reviews have shown that patients with substance abuse disorders have experienced negative attitudes from their health care providers. Negative attitudes may lead to less involvement from the provider and the patient and may lead to less effective care. Using case vignettes with a SAS workshop may be an effective method to help people learn about addiction, reduce the stigma toward addiction and improve the quality of health care.

Study Overview

• Status: Completed
• Conditions: Malignant Solid Neoplasm; Hematopoietic and Lymphatic System Neoplasm
• Intervention / Treatment: Behavioral: Assessment; Other: Educational Activity; Other: Educational Activity; Other: Educational Activity; Other: Educational Activity; Other: Educational Activity; Other: Educational Activity; Other: Training

Detailed Description

PRIMARY OBJECTIVE:

I. To describe the impact of SAS training on participants' responses to people with a substance impairment.

SECONDARY OBJECTIVES:

I. To evaluate the feasibility of stigma training workshops on stigmatizing attitudes health care personnel.

II. To explore the maintainability of responses over time. III. To explore relationships between language and stigmatizing attitudes.

OUTLINE: Participants are randomized to 1 of 6 group case vignettes.

GROUP A (CHRONICALLY RELAPSING BRAIN DISEASE): Participants view the chronically relapsing brain disease vignette and attend a SAS workshop on study.

GROUP B (BRAIN DISEASE): Participants view the brain disease vignette and attend a SAS workshop on study.

GROUP C (DISEASE): Participants view the disease vignette and attend a SAS workshop on study.

GROUP D (ILLNESS): Participants view the illness vignette and attend a SAS workshop on study.

GROUP E (DISORDER): Participants view the disorder vignette and attend a SAS workshop on study.

GROUP F (PROBLEM): Participants view the problem vignette and attend a SAS workshop on study.

• Study Type: Interventional
• Enrollment (Actual): 93
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Ohio
    • Columbus, Ohio, United States, 43210
      • Ohio State University Comprehensive Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Employee of Ohio State University Wexner Medical Center (OSUWMC)
• Age ≥ 18 years
• Participants must be able to read and comprehend survey items

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Health Services Research
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group A (chronically relapsing brain disease vignette, SAS); Participants view the chronically relapsing brain disease vignette and attend a SAS workshop on study.	Behavioral: Assessment; Ancillary studies; Other Names: Assess; Study Assessment; Study Observation; Other: Educational Activity; View the chronically relapsing brain disease vignette; Other: Educational Activity; View the brain disease vignette; Other: Educational Activity; View the disease vignette; Other: Educational Activity; View the illness vignette; Other: Educational Activity; View the disorder vignette; Other: Educational Activity; View the problem vignette
Experimental: Group B (brain disease vignette, SAS); Participants view the brain disease vignette and attend a SAS workshop on study.	Behavioral: Assessment; Ancillary studies; Other Names: Assess; Study Assessment; Study Observation; Other: Educational Activity; View the chronically relapsing brain disease vignette; Other: Educational Activity; View the brain disease vignette; Other: Educational Activity; View the disease vignette; Other: Educational Activity; View the illness vignette; Other: Educational Activity; View the disorder vignette; Other: Educational Activity; View the problem vignette; Other: Training; Attend a SAS workshop; Other Names: Training Programs
Experimental: Group C (disease vignette, SAS); Participants view the disease vignette and attend a SAS workshop on study.	Behavioral: Assessment; Ancillary studies; Other Names: Assess; Study Assessment; Study Observation; Other: Educational Activity; View the chronically relapsing brain disease vignette; Other: Educational Activity; View the brain disease vignette; Other: Educational Activity; View the disease vignette; Other: Educational Activity; View the illness vignette; Other: Educational Activity; View the disorder vignette; Other: Educational Activity; View the problem vignette; Other: Training; Attend a SAS workshop; Other Names: Training Programs
Experimental: Group D (illness vignette, SAS); Participants view the illness vignette and attend a SAS workshop on study.	Behavioral: Assessment; Ancillary studies; Other Names: Assess; Study Assessment; Study Observation; Other: Educational Activity; View the chronically relapsing brain disease vignette; Other: Educational Activity; View the brain disease vignette; Other: Educational Activity; View the disease vignette; Other: Educational Activity; View the illness vignette; Other: Educational Activity; View the disorder vignette; Other: Educational Activity; View the problem vignette; Other: Training; Attend a SAS workshop; Other Names: Training Programs
Experimental: Group E (disorder vignette, SAS); Participants view the disorder vignette and attend a SAS workshop on study.	Behavioral: Assessment; Ancillary studies; Other Names: Assess; Study Assessment; Study Observation; Other: Educational Activity; View the chronically relapsing brain disease vignette; Other: Educational Activity; View the brain disease vignette; Other: Educational Activity; View the disease vignette; Other: Educational Activity; View the illness vignette; Other: Educational Activity; View the disorder vignette; Other: Educational Activity; View the problem vignette; Other: Training; Attend a SAS workshop; Other Names: Training Programs
Experimental: Group F (problem vignette, SAS); Participants view the problem vignette and attend a SAS workshop on study.	Behavioral: Assessment; Ancillary studies; Other Names: Assess; Study Assessment; Study Observation; Other: Educational Activity; View the chronically relapsing brain disease vignette; Other: Educational Activity; View the brain disease vignette; Other: Educational Activity; View the disease vignette; Other: Educational Activity; View the illness vignette; Other: Educational Activity; View the disorder vignette; Other: Educational Activity; View the problem vignette; Other: Training; Attend a SAS workshop; Other Names: Training Programs

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Stigmatizing attitudes	Stigmatizing attitudes will be measured with the Stigma and Attribution Assessment. The assessment score will be compared both between and within participants for each case vignette. Results will be reported with descriptive statistics, including means and standard deviations or medians and first-third quartiles for continuous variables, and frequencies and percentages for discrete variables.The linear mixed effect model will be used to study the repeated stigma and attribution measures over time (pre-workshop, immediately post-workshop, and 8 weeks post-workshop) within 6 vignettes as well as the effects between the vignettes, while controlling for the potential confounding factors (e.g., sex).	Before, immediately after and 8 weeks after the session

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Attendance rate	The proportion of participants attending the workshop will be summarized with 95% confidence interval.	At 90 minute session.
Response to post-workshop evaluations	The proportion of participants who respond to the post-workshop evaluations will be summarized with 95% confidence interval.	Before, immediately following and 8 weeks after the session.

Collaborators and Investigators

• Sponsor: Ohio State University Comprehensive Cancer Center
• Investigators: Principal Investigator: Gretchen A Mcnally, PhD, APRN-CNP, Ohio State University Comprehensive Cancer Center

Publications and helpful links

Helpful Links

• The Jamesline

Study record dates

Study Major Dates

• Study Start (Actual): October 17, 2023
• Primary Completion (Actual): December 31, 2023
• Study Completion (Actual): December 31, 2023

Study Registration Dates

• First Submitted: June 27, 2024
• First Submitted That Met QC Criteria: August 29, 2024
• First Posted (Actual): September 3, 2024

Study Record Updates

• Last Update Posted (Actual): September 3, 2024
• Last Update Submitted That Met QC Criteria: August 29, 2024
• Last Verified: August 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: OSU-23194; NCI-2024-04797 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No